Navigation Links
Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
Date:7/25/2008

of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborator, in connection with the development and commercialization of Genaera's IL-9 antibody program; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any
'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
11. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... 21, 2014  Aptuit LLC announces that Aptuit ... , has enhanced its capabilities in the ... and large molecules, including biologic drugs, metabolites, and ... Q-TOF mass spectrometer. In making the ... said, "The expanded large molecule capability enhances our ...
(Date:8/21/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... health, has appointed Holly B. Bauzon as ... Ms. Bauzon has a proven track record in both ... services companies. She has more than 20 years of ... held the position of Director, Lab Services Sales and ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... announced that its Board of Directors has appointed Dirk Allison ...  Mr. Allison has been the interim CEO of the Company ... joining CCS Medical as its President and Chief Executive Officer," ... and I look forward to continuing our growth in diabetes, ...
... March 21, 2011 Echo Therapeutics, Inc. (OTC Bulletin ... needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, today announced results for ... on Form 10-K is available through Echo,s website at ...
Cached Medicine Technology:Echo Therapeutics Announces 2010 Financial Results 2Echo Therapeutics Announces 2010 Financial Results 3Echo Therapeutics Announces 2010 Financial Results 4
(Date:8/22/2014)... 2014 Recently, iFitDress.com, a well-known wedding ... of discounted wedding gowns . In addition to ... these new products are provided with low shipping fees. ... to unveil the new wedding gowns. In our online ... for ladies to choose from. What’s more, all of ...
(Date:8/22/2014)... New Orleans, LA The LSU Health New ... Advanced Education Nursing Traineeship grant to increase access ... disadvantaged, underserved and under-represented groups, as well as ... the US Department of Health and Human Services ... will serve as the grant,s project director., The ...
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Restore My Vision Today , ... Pearson to help people discover how they can get ... by instead improving their eyesight naturally has caught the ... , “There’s a reason why the glasses and contacts ... because people just assume that it’s their only option ...
Breaking Medicine News(10 mins):Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2
... disease could be more common than thought, experts say, , ... from rabies of a 17-year-old Texas girl -- diagnosed months ... their heads and wondering if such cases might be less ... possibility that abortive rabies can occur in humans and might ...
... ... enterprise platform for its revolutionary Evercore® – Enterprise Clinical Suite software system, now available ... ... Healthcare Technology , a leading medical informatics company, has launched a new enterprise platform ...
... ... ... ... ...
... , ... ... ... ...
... screening tool for early detection of prostate cancer (PCa) in ... PCa. The risk of suicide is increased among cancer patients ... among men diagnosed with PCa subsequent to PSA testing, a ... published in the March issue of European Urology , ...
... Two Spanish psychologists and a German neurologist have recently shown ... new noun is different from the part used when a ... taken using functional magnetic resonance, according to an article they ... "Learning nouns activates the left fusiform gyrus, while learning ...
Cached Medicine News:Health News:Texas Girl Recovers From Rabies Without Intensive Care 2Health News:TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 2Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 3Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 4Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 5Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 6Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 7Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 8Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 9Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 10Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 11Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 12Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 13Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 14Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 15Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 16Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 17Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 18Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 19Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 20Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 21Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 22Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 23Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 24Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 25Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 26Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 27Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 28Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 29Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 30Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 31Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 32Health News:US Oncology Reports 2009 Fourth Quarter and Year End Operating Results 33Health News:MedTrust Online Brings MICROMEDEX(R) DRUGDEX(R) From Thomson Reuters to Over 7,000 Online Oncologists 2
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
... Hydroview™ hydrophilic acrylic IOL is the ... truly designed with the patient and surgeon ... a hydrogel optic polymerically crosslinked with PMMA ... use, and excellent visual performance and biocompatibility. ...
BIGBAG Hydrophilic Acrylic Lens for high myopia....
... Collamer™ lens, model CQ2003V, combines the best ... This lens contains a Collamer optic with ... angulation. These loops offer flexibility comparable to ... strength, and superior "shape memory". The light ...
Medicine Products: